News Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
19.85 ^USD	+2.06%		+2.48%	-27.84%

Apr. 15	Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	MT
Feb. 26	Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024	Apr. 22	BU
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance	Apr. 22	BU
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024	Apr. 16	BU
Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines	Feb. 27	BU
Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	Feb. 26	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Feb. 23	MT
Needham Raises Price Target on Veracyte to $33 From $30, Maintains Buy Rating	Feb. 23	MT
Veracyte's Q4 Loss Widens, Revenue Increases; Issues 2024 Revenue Outlook; Shares Down Pre-Bell	Feb. 23	MT
Veracyte: Q4 Earnings Snapshot	Feb. 22	AQ
Transcript : Veracyte, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (VCYT) VERACYTE Reports Q4 Revenue $98.2M, vs. Street Est of $92.8M	Feb. 22	MT
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024	Feb. 22	CI
Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results	Feb. 22	BU
Veracyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference	Feb. 21	BU
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	Feb. 13	CI
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	Feb. 08	BU
Veracyte Closes $70 Million C2i Genomics Acquisition	Feb. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Veracyte, Inc.

Equities

VCYT

US92337F1075

Summary

Filters